Enosis and OVID To Launch In-Clinic Pilot Offering of Psychedelic-Augmented Psychotherapy Leveraging Virtual Reality Technology MELBOURNE, Australia, Oct. 31, 2022 /PRNewswire/ — Enosis Therapeutics, (or ‘Enosis’), a medical technology and psychedelic research company that leverages virtual reality (VR) for the contextual modulation of psychedelic therapy to improve treatment outcomes…


Previous articleLusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
Next articleFree Webinar – NueLife: Empowering Patients with At-Home Ketamine Therapy